Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Almirall ( (ES:ALM) ) has shared an announcement.
Almirall has announced the divestment of its product Algidol® and the licensing of Sekisan® in Spain, receiving €12 million upfront and additional future payments. This move is part of Almirall’s strategy for portfolio rotation and management, potentially streamlining its focus and enhancing financial flexibility.
More about Almirall
Almirall is a pharmaceutical company focusing on the development and marketing of medical products. The company specializes in dermatology and other therapeutic areas, providing treatments for a variety of health conditions.
YTD Price Performance: 17.08%
Average Trading Volume: 3,882
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €2.03B
See more insights into ALM stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money